Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced-
stage metastatic melanoma, as well as patients with many other solid cancers, yielding long …

Immunotherapy induces durable responses in a subset of patients with cancer. High tumor
mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors …

Purpose: Therapeutic blockade of immune checkpoints has revolutionized cancer treatment.
Durable responses, however, occur in less than half of those treated, and efforts to improve …

Outcomes for patients with melanoma have improved over the past decade as a result of the
development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte …

Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in
cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by …

Understanding the mechanisms of acquired resistance to anti-PD-1 will allow development
of better treatment strategies for cancer patients. This study evaluated potential mechanisms …

It is obvious that tumor cells have developed a number of strategies to escape immune
surveillance including an altered expression of various immune checkpoints, such as the …

The relation between tumor mutation burden (TMB) and outcome of cancer patients
receiving immunotherapy has been reported. This study aimed to evaluate the prognostic …

Background Programmed cell death protein 1 (PD-1) antibody treatment is standard of care
for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients …